Partners

 

Animal models

 

 

Phenos GmbH

Contract research organisation offering services and research expertise to pharmaceutical companies and academia. PHENOS core expertise is the physiological and pathological analysis of mice and rat models. Using its long lasting experience in in-vivo models, Phenos provides its sophisticated expertise in three major areas:

  • Phenotypical analysis of genetic altered mice (e.g. knock-out animals)
  • Preclinical in-vivo evaluation of new drug compounds
  • Identification of new therapeutic strategies of approved drugs
  • Animal models for the study of kidney disease

 

Cell-Based Assay Services

 

 

Kitos biotech s.r.l.s.

Cell-Based Assay Services for Anticancer Drug Discovery Research.

The goal of Kitos is to assist customers in discovering innovative therapeutic products in an efficient, cost effective manner. ​Kitos has a well-equipped facility with cutting-edge technologies and a team of expert and dedicated scientists.

 

Antibody Specificity Assessment

 

 

Cambridge Protein Arrays Ltd.

Cambridge Protein arrays is a CRO offering analysis services based on complex human protein arrays. While the antibody arrays of Sciomics can be used to profile the content of proteins in a sample, recombinant protein arrays are especially useful for the interpretation of binding parameters of antibodies or auto-antibodies to a human proteins. Such arrays provide ultimate insights in the specificity of an antibody and information on eventual cross-binding events.

   

PEPperPRINT GmbH

Pepperprint offers standard and customized peptide microarrays with their proprietary LASER peptide printing technology which combines high spot densities with content flexibility, production speed and quality in a uniquely cost-effective manner. 
 

 

Recombinant antibodies

 

  
   

YUMAB GmbH

YUMAB provides tailored solutions for human antibody development and antibody engineering problems. YUMAB provides rapid, large-scale discovery and optimization of human monoclonal antibodies, custom libraries, antibody engineering (e.g., humanization, affinity maturation, various antibody product formats), and custom-made antibodies to difficult antigen targets. YUMAB offers fee-for-service solutions, and attractive and flexible licensing options for diagnostics and therapeutics. 

 

Instrumentation

 

 

DITABIS AG

DITABIS entwickelt und fertigt auf der Basis von OEM-Partnerschaften Medizingeräte, Laborgeräte oder Imagingsysteme für Anwendungen in den Bereichen Health Care, Life Science und In-Vitro-Diagnostik.

 

 

 

 

 Research projects

 

 

MCDS-Therapy (@MCDS-Therapy)

A Horizon 2020 funded 5-year clinical trial for the repurposing of carbamazepine for the treatment of metaphyseal chondrodysplasia, type Schmid.

> Read our press release

     

 

 

 

Networks

 

 

BIO Deutschland

As the sector association of the biotechnology industry, BIO Deutschland has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences.

   

DECHEMA

DECHEMA is the expert network for chemical engineering and biotechnology in Germany. As a non-profit professional society we represent these fields in science, industry, politics and the general public. DECHEMA promotes scientific and technical exchange among experts from different disciplines, organisations and generations. We consolidate the know-how of over 5,800 individual and sustaining members.

 

BioRN

Over the past few years the Rhine-Neckar biotech region has developed into one of Germany’s strongest biotechnology clusters. The cluster is located within a radius of 30 km around the cities of Heidelberg, Mannheim, Darmstadt and Ludwigshafen. It is the most prominent and concentrated biotech cluster in Germany in the fields of personalized medicine and cancer research.

 

Technologiepark Heidelberg

Heidelberg Technology Park is a science park where major research institutes and global corporations work side by side. The synergies are manifold so that what emerges is a science-based society in which science finds scope for experimentation in industry and scientific research gains new perspectives as a result of international cooperation.

 

BioLAGO e.V.

BioLAGO is the cross-border health network for life sciences in the four-country-region of Lake Constance (Germany, Switzerland, Austria and Liechtenstein). The network links industry with science for innovations; it promotes knowledge transfer and the foundation of new firms.

 

Network Lab-on-a-Chip Technologies

Lab-on-a-Chip approaches (short: LoaC) are the combination and integration of several analytical steps of classical and new laboratory analysis on a glass, silicium or plastic chip. The goal is to achiev a high degree of automation as well as the parallelization of many analytical steps (keyword " High Content Screening").

The network focuses on innovative products, production processes and services primarily in the fields of

  • Point-of-care diagnostics systems / Biomarker development
  • Replacement of animal experiments by "organ-on-a-chip" approaches
  • cell analysis / microbiology
  • chip manufacturing

 

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1,300 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels…
Read more
scioDiscover - Protein Profiling on expression level

scioDiscover - Protein Profiling on expression level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell surface marker and Cytokine profiling

scioCD - Cell surface marker and Cytokine profiling

  Characterise a certain cell type?   Cell composition in a certain tissue sample?   In-depth profiling of CD-marker expression?   Increase your throughput at high sensitivity levels? You aim…
scioUbi

scioUbi

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay.   Features Screen…
scioCyto : Cytokine profiling

scioCyto : Cytokine profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or…

COVID-19 related activities and services

covid 19 portfolio web

News

New article | Prevention of Cyclosp.-A mediated anemia and peritubular loss

| June 2022 | In a study by Robert Labes et al. insights in prevention of cyclosporine mediated anemia and peritubular capillary loss were identified.

Labes, R. et al. Daprodust. prevents cyclosp.-A mediated anemia and peritubular capillary loss. Kidney International 2022 in press.
New article | The Lifestyle Modifications Affect the Endometrial Proteome

| June 2022 | In a study by D. Abdulkhalikova et al. Endometrial Proteome changes werde identified impacted by Lifestyle modification in woman with Polycystic Ovarian Syndrome and Obesity.

Abdulkhalikova, DR. et al. The Lifestyle Modifications and Endometrial Proteome Changes of Women With Polycystic Ovary Syndrome and Obesity. Front. Endocrinol. 2022 in press.
New article | Cycle-dependent biomarkers in endometriosis

| May 2022 | In a study by Maja Pušić et al. Cycle-dependent plasma protein biomarkers for peritoneal endometriosis were identified by our scioDiscover platform.

Pušić, M. et al. Antibody Arrays Identified Cycle-Dependent Plasma Biomarker Candidates of Peritoneal Endometriosis. J. Pers. Med. 202212, 852.
New article | Co-Expression of microRNAs and Proteins in Alzheimer’s Disease

| Jan 2022 | In a study by Valentina di Pietro at Birmingham University our scioDoiscover platform was used to analyse the co-expression of proteins and microRNAs in the brains of Alzheimer's disease patients.

Watson, C. N. et al. Co-Expression Analysis of microRNAs and Proteins in Brain of Alzheimer’s Disease Patients. Cells 11, 163 (2022).
New article | ETV6 levels predict outcome in DLBCL

| Jan 2022 | Erich Piovan and collegues at University of Padua collaborated with Sciomics to study specific biomarkers in FFPE tissue samples of DLBCL patients by custom antibody microarrays.

Marino, D. et al. High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients. Cancers 14, (2022).

Testimonials

Dr. Felix Czernilofsky

Department of Medicine V, Heidelberg University Hospital,Heidelberg, Germany

"The scioCyto assay from Sciomics was a tremendous help in characterizing complex supernatants of in vitro tumor microenvironment models. With the professional, fast and friendly support from Ronny and colleagues we were able to confirm and extend our hypotheses. I am very happy to recommend the Sciomics experience!"

Product: scioCyto

 

Dr. Anke König

Clinics for dermatology, venerology and allergology, University Clinics Frankfurt, Frankfurt, Germany

"We enjoyed working with Sciomics on various research projects related to inflammatory skin diseases. The cooperation with Sciomics was just excellent. In addition to processing the samples and compiling the data in a perfectly understandable way, Sciomics GmbH supports us with the entire interpretation and presentation of our results with lots of ideas beyond the usual level of corporate performance. We are looking forward to developing new ideas for further clinical studies together."

Product: scioDiscover

 

Tweets

  • 4 days ago

    Thank you Harald H.H.W. Schmidt and all partners for bringing together this consortium and making this initiative p… https://t.co/SdNazVcniO

  • 4 days ago

    Sciomics - Enabling Precision Medicine will contribute to the initiative with its expertise and platform for protei… https://t.co/N9w228VRcF

  • 4 days ago

    During the next 7 years, 28 partners from 10 countries will join forces to make REPO4EU a reality and create a uniq… https://t.co/zLPRdQHR34

  • 4 days ago

    We are proud to be a partner in the new initiative @repo4eu selected and granted almost €23M by the EC. REPO4EU's… https://t.co/IVWuHwUqm1

  • 22 days ago

    RT @JPM_MDPI: Article: Antibody Arrays Identified Cycle-Dependent Plasma #Biomarker Candidates of Peritoneal #Endometriosis by Prof. Dr. Te…